18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.
This prospective pilot study aimed to evaluate the predictive value of (18)F-FDG PET/CT for early diagnosis of acute gastrointestinal GVHD (GI-GVHD). In all, 42 consecutive patients who received allo-SCT were included. (18)F-FDG PET/CT was systematically performed at a median of 28 (range, 24-38) days after allo-SCT. (18)F-FDG PET/CT data review was positive in 15 cases (36%) (9 true positive (TP) cases and 6 false positive (FP) cases) and negative in 27 cases (64%; 26 true negative (TN) cases and 1 false negative (FN) case) at visual analysis. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of (18)F-FDG PET/CT for the diagnosis of acute GI-GVHD were, respectively, 81%, 90%, 60%, 96% and 83%. There were no significant differences of SUVmax values between grade 1-2 GI-GVHD and severe grade 3-4 GI-GVHD. Overall, these preliminary findings suggested that the inflammatory activity of the gastrointestinal tract associated with acute GI-GVHD could be assessed by (18)F-FDG PET/CT suggesting that noninvasive (18)F-FDG PET/CT could become a valuable examination to be performed shortly before endoscopy to map acute GI-GVHD lesions, guide the biopsy sites and choose the appropriate endoscopic procedure, especially in those asymptomatic patients with a positive (18)F-FDG PET/CT.
1] Centre Hospitalier et Universitaire (CHU) de Nantes, Service de Médecine Nucléaire Nantes, Nantes, France [2] Université de Nantes, Faculté de Médecine, Nantes, France [3] INSERM CRNCA UMR 892, Nantes, France.
C
C
Bodet-Milin
ICO René Gauducheau, Service de Médecine nucléaire, Saint Herblain/Nantes, France.
M
M
Lacombe
1] INSERM CRNCA UMR 892, Nantes, France [2] Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
F
F
Malard
Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
E
E
Lestang
Centre Hospitalier et Universitaire (CHU) de Rennes, Service d'Hématologie Clinique, Rennes, France.
X
X
Cahu
Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
P
P
Chevallier
Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
T
T
Guillaume
Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
J
J
Delaunay
1] INSERM CRNCA UMR 892, Nantes, France [2] Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France.
E
E
Brissot
1] Université de Nantes, Faculté de Médecine, Nantes, France [2] INSERM CRNCA UMR 892, Nantes, France [3] Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France [4] Centre d'Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France.
P
P
Moreau
1] Centre Hospitalier et Universitaire (CHU) de Nantes, Service de Médecine Nucléaire Nantes, Nantes, France [2] Université de Nantes, Faculté de Médecine, Nantes, France [3] INSERM CRNCA UMR 892, Nantes, France [4] ICO René Gauducheau, Service de Médecine nucléaire, Saint Herblain/Nantes, France [5] Centre d'Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France.
F
F
Kraeber-Bodere
1] Université de Nantes, Faculté de Médecine, Nantes, France [2] INSERM CRNCA UMR 892, Nantes, France [3] Centre Hospitalier et Universitaire (CHU) de Nantes, Service d'Hématologie Clinique, Nantes, France [4] Centre d'Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France [5] Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, Paris, France [6] Université Pierre et Marie Curie, Paris, France [7] INSERM, UMRs 938, Paris, France.
M
M
Mohty
D000328:Adult; D000368:Aged; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18; D005767:Gastrointestinal Diseases / Q000000981:diagnostic imaging*; D006086:Graft vs Host Disease / Q000000981:diagnostic imaging*; D006402:Hematologic Diseases / Q000150:complications / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D010865:Pilot Projects; D049268:Positron-Emission Tomography; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed; D019172:Transplantation Conditioning; D055815:Young Adult
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18